Hacker News Reader

If it benefits or isn’t detrimental to shareholders..

Given that Sickle Cell Disease only affects ~20 million people in the entire world [1], and beta-thalassemia affects even fewer (maybe ~200,000 people) [2], and that this treatment currently costs millions of dollars per person, I think shareholders will be just fine.

[1] https://www.nhlbi.nih.gov/health/sickle-cell-disease

[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893117/

Doesn't it only affect Africans?

The trait is present in up to 3% of births in some parts of sub-Saharan Africa.

In America

* About 1 in 13 black babies are born with sickle cell trait.

* About 1 in every 365 black babies are born with sickle cell disease.

* People who come from Hispanic, Southern European, Middle Eastern, or Asian Indian backgrounds can also have sickle cell disease.

* Of the 74 817 hospitalized for sickle cell disease (2016 to 2018), 69 889 (93.4%) were Blacks, 3603 (4.8%) were Hispanics, and 1325 (1.8%) were Whites.

Reply on news.ycombinator.com